نتایج جستجو برای: egfr genes

تعداد نتایج: 454104  

Journal: :Cancer research 2005
Nobukazu Fujimoto Marie Wislez Jie Zhang Kentaro Iwanaga Jennifer Dackor Amy E Hanna Shailaja Kalyankrishna Dianna D Cody Roger E Price Mitsuo Sato Jerry W Shay John D Minna Michael Peyton Ximing Tang Erminia Massarelli Roy Herbst David W Threadgill Ignacio I Wistuba Jonathan M Kurie

Recent findings in tumor biopsies from lung adenocarcinoma patients suggest that somatic mutations in the genes encoding epidermal growth factor receptor (EGFR) and Kirsten ras (KRAS) confer sensitivity and resistance, respectively, to EGFR inhibition. Here, we provide evidence that these genetic mutations are not sufficient to modulate the biological response of lung adenocarcinoma cells to EG...

Journal: :Archives of Medical Science 2022

Introduction The coal-manufacturing districts in the Eastern Yunnan province of Southwest China are utmost occurrence and death lung tumors. As previously reported on unique clinical characteristics non-small cell cancer (NSCLC) patients from these regions without a clear understanding aetiology molecular characteristics. We aim to identify driver gene mutations spectrum. Material methods Sampl...

2015
Núbia Braga Pereira Ana Carolina de Melo do Carmo Marina Gonçalves Diniz Ricardo Santiago Gomez Dawidson Assis Gomes Carolina Cavalieri Gomes

BACKGROUND Ameloblastoma is a locally invasive neoplasm often associated with morbidity and facial deformities, showing increased Epidermal Growth Factor Receptor (EGFR) expression. Inhibition of EGFR was suggested as a treatment option for a subset of ameloblastomas. However, there are resistance mechanisms that impair anti-EGFR therapies. One important resistance mechanism for EGFR-inhibition...

Journal: :Pathobiology : journal of immunopathology, molecular and cellular biology 2008
Sumitaka Yamanaka Zhaodi Gu Masami Sato Rumi Fujisaki Kenichi Inomata Akira Sakurada Akira Inoue Toshihiro Nukiwa Takashi Kondo Akira Horii

OBJECTIVE To understand the molecular pathogenesis of lung cancer and to establish a novel therapeutic application, we examined the genetic alterations in lung cancer, and studied the effects of gefitinib and siRNA-mediated knockdown of EGFR on lung cancer. METHODS We analyzed mutations in EGFR, KRAS, TP53, and ERBB2 in 198 surgically resected lung cancer specimens. We then analyzed the effec...

Journal: :Histology and histopathology 2012
V Martin F Botta E Zanellato F Molinari S Crippa L Mazzucchelli M Frattini

AIMS Triple negative breast cancer with basal like features (TN-BCBL) do not benefit from hormonal and anti-HER2 therapies. As a considerable fraction of TN-BCBLs shows EGFR deregulation, EGFR-targeted therapies have been proposed as an option. The characterization of EGFR and EGFR-downstream members may therefore provide important predictive information. METHODS AND RESULTS Based on morpholo...

Journal: :Cancer research 2003
Yoshifumi Okada Edward E Hurwitz John M Esposito Melissa A Brower Catherine L Nutt David N Louis

Epidermal growth factor receptor (EGFR) gene amplification occurs in glioblastomas as so-called double minutes. Because double minutes are extrachromosomal fragments, selection pressures must operate to maintain high EGFR copy number over multiple cell divisions. In analyses of glioblastoma lysates, EGFR amplification has been observed almost exclusively in glioblastomas harboring wild-type TP5...

2013
Florent Baty Sacha Rothschild Martin Früh Daniel Betticher Cornelia Dröge Richard Cathomas Daniel Rauch Oliver Gautschi Lukas Bubendorf Susanne Crowe Francesco Zappa Miklos Pless Martin Brutsche

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identification of additional relevant biomarkers. Previous studies on tumor EGFR protein levels and EGFR gen...

Journal: :Annals of Oncology 2022

Despite recent advances in the treatment of mCRC, survival benefit obtained with third-line is modest. Anti-EGFR therapy does not provide mCRC patients whose tumours are mutated respect to RAS genes, and it should be only considered BRAF wild-type patients. Unfortunately, eventually progress due molecular mechanisms acquired resistance, RAS/BRAF mutations EGFR extracellular domain (EGFR-ECD) as...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه تربیت مدرس - دانشکده علوم پزشکی 1388

رشد و گسترش تومورها به مقدار زیادی به فعالیت گیرنده های غشاء سلولی نظیر egfr یا گیرنده رشد اپیدرمال وابسته است. egfr یک نقش کلیدی در اکثر فرآیندهای سلولی درگیر در گسترش تومور دارد و بعنوان یک هدف امیدوار کننده برای درمان سرطان می باشد. ایمونوتراپی یکی از بهترین استراتژیها در درمان سرطان می باشد و ایمونوتوکسین ها در این میان از جایگاه برجسته ای برخوردار هستند . برای تولید آنتی بادی مونو کلونا...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید